SG Americas Securities LLC Purchases Shares of 14,098 Cardlytics, Inc. (NASDAQ:CDLX)

SG Americas Securities LLC acquired a new stake in Cardlytics, Inc. (NASDAQ:CDLX) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 14,098 shares of the company’s stock, valued at approximately $45,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Brooktree Capital Management grew its position in shares of Cardlytics by 18.0% in the first quarter. Brooktree Capital Management now owns 138,970 shares of the company’s stock valued at $2,014,000 after purchasing an additional 21,150 shares during the last quarter. ClariVest Asset Management LLC bought a new position in Cardlytics during the 1st quarter worth $707,000. Susquehanna Fundamental Investments LLC lifted its holdings in shares of Cardlytics by 13.8% during the first quarter. Susquehanna Fundamental Investments LLC now owns 31,536 shares of the company’s stock worth $457,000 after buying an additional 3,836 shares in the last quarter. Banco Santander S.A. bought a new stake in shares of Cardlytics in the first quarter valued at about $199,000. Finally, Vanguard Group Inc. boosted its position in shares of Cardlytics by 2.7% in the first quarter. Vanguard Group Inc. now owns 2,211,595 shares of the company’s stock valued at $32,046,000 after acquiring an additional 57,805 shares during the period. 68.10% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Scott A. Hill acquired 40,000 shares of the stock in a transaction that occurred on Monday, August 12th. The stock was acquired at an average cost of $3.58 per share, for a total transaction of $143,200.00. Following the transaction, the director now directly owns 40,000 shares in the company, valued at $143,200. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director Scott A. Hill bought 40,000 shares of the firm’s stock in a transaction on Monday, August 12th. The shares were purchased at an average price of $3.58 per share, with a total value of $143,200.00. Following the completion of the purchase, the director now owns 40,000 shares in the company, valued at $143,200. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Amit Gupta sold 22,607 shares of the stock in a transaction on Thursday, October 24th. The shares were sold at an average price of $3.85, for a total value of $87,036.95. Following the completion of the transaction, the chief executive officer now owns 178,519 shares of the company’s stock, valued at $687,298.15. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 43,573 shares of company stock worth $151,612. Corporate insiders own 4.40% of the company’s stock.

Cardlytics Stock Performance

Shares of NASDAQ:CDLX opened at $3.99 on Wednesday. Cardlytics, Inc. has a 1 year low of $2.89 and a 1 year high of $20.52. The stock has a market capitalization of $194.64 million, a price-to-earnings ratio of -0.90 and a beta of 1.67. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.77 and a quick ratio of 1.77. The company’s 50 day simple moving average is $3.62 and its 200 day simple moving average is $7.07.

Cardlytics (NASDAQ:CDLX) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.12. The company had revenue of $69.64 million during the quarter, compared to analysts’ expectations of $75.39 million. Cardlytics had a negative return on equity of 17.96% and a negative net margin of 50.21%. Cardlytics’s revenue was down 9.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.57) EPS. As a group, research analysts predict that Cardlytics, Inc. will post -1.72 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. Bank of America cut shares of Cardlytics from a “neutral” rating to an “underperform” rating and dropped their price objective for the stock from $4.00 to $3.50 in a research note on Thursday, August 15th. Craig Hallum cut Cardlytics from a “buy” rating to a “hold” rating in a research note on Thursday, August 8th. Northland Capmk downgraded Cardlytics from a “strong-buy” rating to a “hold” rating in a research report on Friday, August 16th. Lake Street Capital cut Cardlytics from a “buy” rating to a “hold” rating and dropped their price objective for the company from $18.00 to $5.00 in a report on Thursday, August 8th. Finally, Northland Securities lowered Cardlytics from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $7.00 to $5.00 in a report on Friday, August 16th. One research analyst has rated the stock with a sell rating and six have assigned a hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $6.92.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.